142 related articles for article (PubMed ID: 32022317)
1. TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice.
Johanna I; Hernández-López P; Heijhuurs S; Bongiovanni L; de Bruin A; Beringer D; van Dooremalen S; Shultz LD; Ishikawa F; Sebestyen Z; Straetemans T; Kuball J
J Leukoc Biol; 2020 Jun; 107(6):1069-1079. PubMed ID: 32022317
[TBL] [Abstract][Full Text] [Related]
2. Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control.
Johanna I; Hernández-López P; Heijhuurs S; Scheper W; Bongiovanni L; de Bruin A; Beringer DX; Oostvogels R; Straetemans T; Sebestyen Z; Kuball J
Front Immunol; 2021; 12():752699. PubMed ID: 34759930
[TBL] [Abstract][Full Text] [Related]
3. Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells.
Johanna I; Straetemans T; Heijhuurs S; Aarts-Riemens T; Norell H; Bongiovanni L; de Bruin A; Sebestyen Z; Kuball J
J Immunother Cancer; 2019 Mar; 7(1):69. PubMed ID: 30871629
[TBL] [Abstract][Full Text] [Related]
4. Identification of a tumor-specific allo-HLA-restricted γδTCR.
Kierkels GJJ; Scheper W; Meringa AD; Johanna I; Beringer DX; Janssen A; Schiffler M; Aarts-Riemens T; Kramer L; Straetemans T; Heijhuurs S; Leusen JHW; San José E; Fuchs K; Griffioen M; Falkenburg JH; Bongiovanni L; de Bruin A; Vargas-Diaz D; Altelaar M; Heck AJR; Shultz LD; Ishikawa F; Nishimura MI; Sebestyén Z; Kuball J
Blood Adv; 2019 Oct; 3(19):2870-2882. PubMed ID: 31585951
[TBL] [Abstract][Full Text] [Related]
5. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
[TBL] [Abstract][Full Text] [Related]
6. Human CD4+ HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo.
Pankratz S; Bittner S; Herrmann AM; Schuhmann MK; Ruck T; Meuth SG; Wiendl H
FASEB J; 2014 Aug; 28(8):3435-45. PubMed ID: 24744146
[TBL] [Abstract][Full Text] [Related]
7. Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells.
Dawson NA; Lamarche C; Hoeppli RE; Bergqvist P; Fung VC; McIver E; Huang Q; Gillies J; Speck M; Orban PC; Bush JW; Mojibian M; Levings MK
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30753169
[TBL] [Abstract][Full Text] [Related]
8. Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease.
Stamou P; Marioli D; Patmanidi AL; Sgourou A; Vittoraki A; Theofani E; Pierides C; Taraviras S; Costeas PA; Spyridonidis A
Cytotherapy; 2017 Apr; 19(4):521-530. PubMed ID: 28162915
[TBL] [Abstract][Full Text] [Related]
9. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
Front Immunol; 2019; 10():2717. PubMed ID: 31824502
[TBL] [Abstract][Full Text] [Related]
10. Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy.
Yuan M; Wang W; Hawes I; Han J; Yao Z; Bertaina A
Front Immunol; 2024; 15():1360237. PubMed ID: 38576617
[TBL] [Abstract][Full Text] [Related]
11. Universal cytotoxic activity of a HTLV-1 Tax-specific T cell clone from an HLA-A*24:02⁺ patient with adult T-cell leukemia against a variety of HTLV-I-infected T-cells.
Tanaka Y; Yamazaki R; Terasako-Saito K; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Sato M; Kimura S; Kikuchi M; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
Immunol Lett; 2014; 158(1-2):120-5. PubMed ID: 24389072
[TBL] [Abstract][Full Text] [Related]
12. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
Lemmermann NA; Reddehase MJ
Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
[TBL] [Abstract][Full Text] [Related]
13. Chronic graft-versus-host-disease in CD34(+)-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease.
Sonntag K; Eckert F; Welker C; Müller H; Müller F; Zips D; Sipos B; Klein R; Blank G; Feuchtinger T; Schumm M; Handgretinger R; Schilbach K
J Autoimmun; 2015 Aug; 62():55-66. PubMed ID: 26143958
[TBL] [Abstract][Full Text] [Related]
14. Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor.
Marcu-Malina V; Heijhuurs S; van Buuren M; Hartkamp L; Strand S; Sebestyen Z; Scholten K; Martens A; Kuball J
Blood; 2011 Jul; 118(1):50-9. PubMed ID: 21566093
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
16. Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.
Ali R; Babad J; Follenzi A; Gebe JA; Brehm MA; Nepom GT; Shultz LD; Greiner DL; DiLorenzo TP
Immunology; 2016 Aug; 148(4):339-51. PubMed ID: 27124592
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy.
Imahashi N; Nishida T; Ito Y; Kawada J; Nakazawa Y; Toji S; Suzuki S; Terakura S; Kato T; Murata M; Naoe T
Mol Immunol; 2013 Dec; 56(4):399-405. PubMed ID: 23911395
[TBL] [Abstract][Full Text] [Related]
18. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis.
Yoshitake Y; Nakatsura T; Monji M; Senju S; Matsuyoshi H; Tsukamoto H; Hosaka S; Komori H; Fukuma D; Ikuta Y; Katagiri T; Furukawa Y; Ito H; Shinohara M; Nakamura Y; Nishimura Y
Clin Cancer Res; 2004 Oct; 10(19):6437-48. PubMed ID: 15475430
[TBL] [Abstract][Full Text] [Related]
19. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
20. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]